INKT MiNK Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1840229 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY10.8%
TTM EPS YoY25.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-95.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets297.2%
Debt / equity—
Current ratio0.97x
Interest coverage317.82x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-33.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $5.76M | $6.34M | $15.49M | $23.12M | $13.97M |
| SG&A expense | $6.73M | $4.31M | $7.43M | $7.83M | $4.64M |
| Operating income | -$12.64M | -$11.29M | -$22.92M | -$30.95M | -$28.36M |
| Interest expense | -$110,000 | -$93,000 | -$28,000 | — | $2.43M |
| Net income | -$12.49M | -$10.78M | -$22.46M | -$27.99M | -$30.21M |
| EBITDA | -$12.46M | -$11.07M | -$22.72M | -$30.83M | -$28.28M |
| EPS (basic) | -2.93 | -2.86 | -6.54 | -0.83 | -1.16 |
| EPS (diluted) | -2.93 | -2.86 | -6.54 | -0.83 | -1.16 |
| Weighted avg. shares (diluted) | 4.27M | 3.77M | 3.44M | 33.67M | 26.03M |
| Banking | |||||
| Net interest income | $180,246 | $172,568 | $463,256 | $253,323 | -$2.43M |
| Balance sheet | |||||
| Cash & equivalents | $13.36M | $4.58M | $3.37M | $19.64M | $38.89M |
| Current assets | $13.85M | $4.99M | $3.60M | $20.40M | $39.63M |
| PP&E, net | $390,869 | $732,929 | $953,977 | $1.07M | $606,595 |
| Total assets | $14.24M | $5.72M | $4.55M | $21.47M | $40.24M |
| Current liabilities | $13.03M | $6.96M | $11.40M | $12.68M | $16.47M |
| Total liabilities | $28.47M | $25.31M | $22.61M | $21.87M | $16.47M |
| Shareholders' equity | -$14.23M | -$19.59M | -$18.06M | -$401,303 | $23.78M |
| Shares outstanding | 4.71M | 3.96M | 3.46M | 33.86M | 33.48M |
| Cash flow statement | |||||
| Operating cash flow | -$5.93M | -$9.56M | -$15.76M | -$18.87M | -$12.83M |
| Capital expenditure | — | — | $73,561 | $250,046 | $248,983 |
| Free cash flow | — | — | -$15.84M | -$19.12M | -$13.08M |
| Investing cash flow | — | — | -$73,561 | -$250,046 | -$248,983 |
| Financing cash flow | $14.72M | $10.82M | -$407,173 | -$155,599 | $49.26M |
| Depreciation & amortization | $181,745 | $215,437 | $204,617 | $121,749 | $77,960 |
| Stock-based compensation | $2.67M | $1.81M | $3.86M | $3.03M | $1.74M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.